<SEC-DOCUMENT>0001213900-24-066357.txt : 20240808
<SEC-HEADER>0001213900-24-066357.hdr.sgml : 20240808
<ACCEPTANCE-DATETIME>20240808092018
ACCESSION NUMBER:		0001213900-24-066357
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20240808
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240808
DATE AS OF CHANGE:		20240808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Citius Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001506251
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				273425913
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38174
		FILM NUMBER:		241186352

	BUSINESS ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016
		BUSINESS PHONE:		(908) 967-6676

	MAIL ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trail One, Inc.
		DATE OF NAME CHANGE:	20110314

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrailOne, Inc.
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0210874-8k_citius.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:CTXR="http://citiuspharma.com/20240808">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_CTXR_citiuspharma.com_20240808 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20240808_20240808 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DEntityCentralIndexKey_0001506251 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-08-08" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-08-08" id="Fact000004" name="dei:EntityCentralIndexKey">0001506251</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ctxr-20240808.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-08-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506251</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-08</xbrli:startDate>
        <xbrli:endDate>2024-08-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNITED STATES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES AND EXCHANGE COMMISSION</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Washington, D.C. 20549</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>FORM <span id="xdx_90C_edei--DocumentType_c20240808__20240808_zFKqz9SGE96l"><ix:nonNumeric contextRef="AsOf2024-08-08" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CURRENT REPORT</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Section 13 or 15(d) of</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">the Securities Exchange Act of 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported)
<span style="text-decoration: underline"><span id="xdx_902_edei--DocumentPeriodEndDate_c20240808__20240808_zs6iw2dFN7Gf"><ix:nonNumeric contextRef="AsOf2024-08-08" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">August 8, 2024</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_904_edei--EntityRegistrantName_c20240808__20240808_zIwuu0q8xWL3"><ix:nonNumeric contextRef="AsOf2024-08-08" id="Fact000011" name="dei:EntityRegistrantName">Citius Pharmaceuticals, Inc.</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="text-decoration: underline"><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20240808__20240808_zW3q60MQ6Yfi"><ix:nonNumeric contextRef="AsOf2024-08-08" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(State or other jurisdiction of incorporation)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration: none"><span id="xdx_904_edei--EntityFileNumber_c20240808__20240808_zCVNQC3OFaLi"><ix:nonNumeric contextRef="AsOf2024-08-08" id="Fact000013" name="dei:EntityFileNumber">001-38174</ix:nonNumeric></span></span></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration: none"><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20240808__20240808_zYLOI17JCHq7"><ix:nonNumeric contextRef="AsOf2024-08-08" id="Fact000014" name="dei:EntityTaxIdentificationNumber">27-3425913</ix:nonNumeric></span></span></span></td>
    </tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Commission File Number)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(IRS Employer <br/>
Identification No.)</span></td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration: none"><span id="xdx_90B_edei--EntityAddressAddressLine1_c20240808__20240808_zIYSk9T4T6X3"><ix:nonNumeric contextRef="AsOf2024-08-08" id="Fact000015" name="dei:EntityAddressAddressLine1">11 Commerce Drive</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressAddressLine2_c20240808__20240808_zLWLSA5UDaO9"><ix:nonNumeric contextRef="AsOf2024-08-08" id="Fact000016" name="dei:EntityAddressAddressLine2">1st Floor</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressCityOrTown_c20240808__20240808_zqtmCxtcnH4c"><ix:nonNumeric contextRef="AsOf2024-08-08" id="Fact000017" name="dei:EntityAddressCityOrTown">Cranford</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressStateOrProvince_c20240808__20240808_zXT1O68xHFTd"><ix:nonNumeric contextRef="AsOf2024-08-08" id="Fact000018" name="dei:EntityAddressStateOrProvince">NJ</ix:nonNumeric></span></span></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration: none"><span id="xdx_907_edei--EntityAddressPostalZipCode_c20240808__20240808_z1dR8Kg7zrz4"><ix:nonNumeric contextRef="AsOf2024-08-08" id="Fact000019" name="dei:EntityAddressPostalZipCode">07016</ix:nonNumeric></span></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">(Address of principal executive offices)</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Zip Code)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&#8217;s telephone number, including area
code <span style="text-decoration: underline">(<span id="xdx_90D_edei--CityAreaCode_c20240808__20240808_zYUmnheS8Xd6"><ix:nonNumeric contextRef="AsOf2024-08-08" id="Fact000020" name="dei:CityAreaCode">908</ix:nonNumeric></span>) <span id="xdx_900_edei--LocalPhoneNumber_c20240808__20240808_zQFSRJHvrlbj"><ix:nonNumeric contextRef="AsOf2024-08-08" id="Fact000021" name="dei:LocalPhoneNumber">967-6677</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif"><span id="xdx_90F_edei--WrittenCommunications_c20240808__20240808_zq2hESYCONHf"><ix:nonNumeric contextRef="AsOf2024-08-08" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif"><span id="xdx_905_edei--SolicitingMaterial_c20240808__20240808_zvYzMrSN474h"><ix:nonNumeric contextRef="AsOf2024-08-08" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif"><span id="xdx_902_edei--PreCommencementTenderOffer_c20240808__20240808_zX3E91TGEbli"><ix:nonNumeric contextRef="AsOf2024-08-08" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif"><span id="xdx_907_edei--PreCommencementIssuerTenderOffer_c20240808__20240808_zgl4So32S64f"><ix:nonNumeric contextRef="AsOf2024-08-08" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%"><span style="text-decoration: none">Title of each class</span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%"><span style="text-decoration: none">Trading Symbol(s)</span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%">Name of each exchange <span style="text-decoration: none">on which registered</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><span id="xdx_90B_edei--Security12bTitle_c20240808__20240808_zh6TD0c7M5yi"><ix:nonNumeric contextRef="AsOf2024-08-08" id="Fact000026" name="dei:Security12bTitle">Common stock, $0.001 par value</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_902_edei--TradingSymbol_c20240808__20240808_zRO9jrFwD4Qg"><ix:nonNumeric contextRef="AsOf2024-08-08" id="Fact000027" name="dei:TradingSymbol">CTXR</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt">The <span id="xdx_90E_edei--SecurityExchangeName_c20240808__20240808_ziTD0myyMEzd"><ix:nonNumeric contextRef="AsOf2024-08-08" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Emerging growth company <span id="xdx_909_edei--EntityEmergingGrowthCompany_c20240808__20240808_zevDf8auM3Vl"><ix:nonNumeric contextRef="AsOf2024-08-08" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Item 8.01 Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">On August 8, 2024, Citius Pharmaceuticals, Inc. issued a press release
to announce that the U.S. Food and Drug Administration has approved LYMPHIR&#8482; (denileukin diftitox-cxdl) for the treatment of relapsed
or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy. A copy of the press release is attached hereto as Exhibit
99.1 and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Item 9.01. Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt">(d)&#160;<span style="text-decoration: underline">Exhibits</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt">The following exhibit is filed
herewith:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-size: 10pt; width: 9%"><span style="font-family: Times New Roman, Times, Serif"><b style="text-decoration: none">Exhibit
    No.</b></span></td>
    <td style="padding-bottom: 1.5pt; white-space: nowrap; font-size: 10pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-size: 10pt; width: 90%"><span style="font-family: Times New Roman, Times, Serif"><b style="text-decoration: none">Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration: none">99.1</span></span></td>
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration: none"><a href="ea021087401ex99-1_citius.htm">Press Release dated August 8, 2024.</a></span></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">104</td>
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify">Cover Page Interactive Date File (embedded within the Inline XBRL document).</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SIGNATURE</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 60%; padding-right: -9pt">&#160;</td>
    <td style="width: 40%; padding-right: -9pt"><span style="font-family: Times New Roman, Times, Serif"><b>CITIUS PHARMACEUTICALS, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">Date: August 8, 2024</span></td>
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration: none">/s/ Leonard Mazur</span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif">Leonard Mazur</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif">Chairman and Chief Executive Officer</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjVEKwkAMRE/QO4T9Ft1WRemfFhWxihQRfxebymK7KdlV2yN5S9cWMQyEMPMyQgzEhta6RIbLMkvhhFVdKoeQYYGM5oo+kWx3Mfid4U1bx8q47vyBCXkGPTMdRmPljS761BbzGOR85BVNQE5jOYPFXgRfPyFT6ByN06oEZXI4MtWs0Slu+w8n1ZChqu2qzshWk4khHMrefkMkwwgO9FQv4ruFNE1EMOgmEBumR+1Tq8ah+ZKwKrHydban/wo+Az1Khg== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea021087401ex99-1_citius.htm
<DESCRIPTION>PRESS RELEASE DATED AUGUST 8, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-size: 10pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="font: 10pt Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Citius Pharmaceuticals
Receives FDA Approval for LYMPHIR&trade; (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory
Cutaneous T-Cell Lymphoma</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Only
systemic treatment for relapsed or refractory (r/r) CTCL to target the IL-2 receptor on malignant T-cells and Tregs</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Calibri, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">LYMPHIR
is expected to launch within the next five months</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Calibri, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">LYMPHIR&#8217;s
approval marks the first novel targeted systemic therapy approved by the FDA r/r CTCL since 2018</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Calibri, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Approval
based on Phase 3 Pivotal Study 302 results that demonstrated 36% ORR, reduction in skin disease in 84% of patients, clinically significant
pruritis improvement, and no cumulative toxicity</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Calibri, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>CRANFORD, N.J.</B>, August 8, 2024 &ndash;
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) (&#8220;Citius&#8221;, &#8220;Citius Pharma&#8221;), announced today that the U.S. Food and
Drug Administration (FDA) has approved LYMPHIR&trade; (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of r/r cutaneous
T-cell lymphoma (CTCL) after at least one prior systemic therapy. LYMPHIR is the only CTCL therapy that targets the interleukin-2 (IL-2)
receptor found on malignant T-cells and Tregs. This is the first indication for LYMPHIR and the first FDA-approved product for Citius
Pharma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#8220;LYMPHIR offers new hope for patients suffering
from cutaneous T-cell lymphoma, a rare and chronic cancer characterized by debilitating skin lesions and severe itching. This approval
is a significant milestone for CTCL patients. The introduction of LYMPHIR, with its potential to rapidly reduce skin disease and control
symptomatic itching without cumulative toxicity, is expected to expand the CTCL treatment landscape and grow the overall market, currently
estimated to be $300-$400 million,&#8221; stated Leonard Mazur, Chief Executive Officer of Citius Pharmaceuticals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#8220;LYMPHIR, with an initial indication in
the treatment of CTCL, is the first of our pipeline candidates to receive FDA approval. Citius is dedicated to working closely with healthcare
providers to ensure that all r/r CTCL patients have timely access to this important new therapy. We are preparing to launch LYMPHIR in
the U.S. market within the next five months,&#8221; added Mazur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#8220;We are grateful to the clinicians, patients,
and researchers who contributed to the development of LYMPHIR. We believe LYMPHIR&#8217;s unique IL-2 receptor-targeted treatment, which
kills tumor cells directly, and concurrently depletes host Tregs in order to boost the body&#8217;s immune response, is an important differentiator
and offers clinically meaningful benefits to a significant percentage of r/r patients. As the only IL-2 receptor-targeted immunotherapy
for CTCL, LYMPHIR provides a novel and non-cross-resistant treatment option without cumulative toxicity for Stage I-III r/r patients for
whom symptomatic skin involvement interferes with their daily quality of life. LYMPHIR&#8217;s median time-to-response of only 1.4 months
(min, max: 0.7, 5.6) offers many patients rapid skin relief,&#8221; added Dr. Myron Czuczman, Chief Medical Officer of Citius Pharmaceuticals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">CTCL is a rare and often debilitating chronic
non-Hodgkin lymphoma that primarily affects the skin. Approximately 2,500-3,000 patients are diagnosed each year with an estimated 40,000
living with the disease. Patients with r/r CTCL have limited treatment options. No universally defined single treatment is used to treat
these patients with incurable cancer. Patients typically cycle through several skin-directed therapies before the cancer becomes resistant
and/or progressive at which point systemic agents are needed to achieve effective disease control. Reducing and controlling skin plaques
and itching without cumulative toxicity is a primary goal of CTCL treatment. Systemic medicines are prescribed until the disease progresses
again or when dose-limiting toxicity occurs, after which HCPs prescribe a different systemic medicine. LYMPHIR provides another viable
option in the treatment landscape with unique benefits to patients. It offers a novel mechanism of action designed to target and eradicate
malignant T-cells while preserving healthy tissue. It is the only treatment option that targets the IL-2 receptors found in T-cell lymphomas
and Tregs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#8220;As a treating oncologist, I have seen
the profound negative effect on the quality of life in patients with r/r CTCL. Given the long-term nature of the disease, pruritus,
ulceration of the tumors, and secondary pyogenic skin infection, it is vital to get this skin involvement under control. LYMPHIR is
the first therapeutic option in many years to offer hope of reducing skin disease, bringing us one step closer to filling the need
for CTCL patients, particularly those that are not able to complete or continue prior therapies,&#8221; stated Dr. Francine Foss,
Professor of Hematology, and Director of the Multidisciplinary T-cell Lymphoma Program at Yale Cancer Center, New
Haven, CT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The approval of LYMPHIR is based on results from
the Phase 3 Pivotal Study 302 (NCT01871727) of CTCL patients who had previously received at least one systemic treatment. Actual study
patients received a median of 4 (min, max: 1, 18) prior anticancer therapies. The primary efficacy population includes 69 patients with
stage I-III CTCL who were treated with denileukin diftitox-cxdl (9 &mu;g /kg/day). The primary efficacy outcome measure was Objective
Response Rate (ORR), as assessed by an Independent Review Committee (IRC). The ORR was 36.2%, (95% CI: 25.0-48.7), with 8.7% achieving
a Complete Response (CR).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The median time to response was rapid at 1.41
months, with the majority of responders (~70%) seeing results after 1&ndash;2 cycles of treatment. Duration of response was at least 6
months for 52.0% of the patients. 84.4% (54/64) of skin evaluable subjects had a decrease in skin tumor burden and 12.5% (8/64) saw complete
clearing of skin disease. Pruritis was evaluated as an exploratory endpoint with 31.7% of patients demonstrating clinically significant
pruritus improvement. Importantly, no cumulative toxicity was observed in patients receiving LYMPHIR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">LYMPHIR&#8217;s safety profile is consistent with
the known safety profile for denileukin diftitox. Across three studies of 119 CTCL patients receiving 9 &mu;g dose of denileukin diftitox,
the most common (&ge;20%) adverse reactions, including laboratory abnormalities, were increased transaminases, albumin decreased, nausea,
edema, hemoglobin decreased, fatigue, musculoskeletal pain, rash, chills, constipation, pyrexia, and capillary leak syndrome (CLS).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>The U.S. Prescribing Information for LYMPHIR
contains a boxed warning that CLS, including life-threatening or fatal reactions, can occur in patients receiving LYMPHIR. Monitor patients
for signs and symptoms of CLS during treatment. Withhold LYMPHIR until CLS resolves, or permanently discontinue based on severity. Additional
&#8220;Important Safety Information&#8221; is available below and LYMPHIR&#8217;s full prescribing information may be accessed here in
the next few days.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This approval includes a postmarketing requirement
from the FDA to characterize the risk of visual impairment in CTCL patients treated with LYMPHIR.&nbsp; Citius is committed to the safety
of patients and will continue to monitor all safety data as it emerges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>About Study 302</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The efficacy of LYMPHIR was evaluated in Study
302, an open-label, single-arm, multicenter trial in patients with r/r Stage I to IV CTCL. Eligible patients were required to have expression
of CD25 on &ge; 20% of biopsied malignant cells by immunohistochemistry<I>. </I>The study excluded patients with significant cardiac disease
or uncontrolled infections. Patients received LYMPHIR at 9 mcg/kg as an intravenous infusion daily from Day 1 through Day 5 of each 21-day
cycle. Patients continued to receive LYMPHIR until disease progression or unacceptable toxicity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The efficacy population includes 69 patients with
r/r Stage I to III CTCL. Of the 69 patients, the median age was 64 years (range: 28 to 87 years), 65% were male, 73% were White, 19% Black
or African American, 1% Asian, and 14% Hispanic or Latino. The CTCL disease stage was IA in 7%, IB in 23%, IIA in 13%, IIB in 35%, IIIA
in 12%, and IIIB in 10%. The median number of prior therapies was 4 (range: 1 to 18), including both skin-directed and systemic therapies.
Prior therapies included photodynamic therapy (56%), total skin electron beam therapy (42%), systemic retinoids (49%), methotrexate/pralatrexate
(49%), histone deacetylase inhibitor (35%), brentuximab vedotin (26%) and mogamulizumab (12%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Efficacy was established based on ORR, according
to ISCL/EORTC Global Response Score (GRS) per Independent Review Committee (Olsen 2011). Efficacy results are shown in the table below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Table: Efficacy Results of Study 302</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: 10pt Aptos; width: 74%; padding-right: 5.75pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Efficacy Endpoint</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; text-align: center; width: 25%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>LYMPHIR </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>9 mcg/kg/day </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>(N=69)</B></P></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 0">ORR (GRS)%<SUP>a</SUP></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">36%</p></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">(95% CI<SUP>b</SUP>)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(25, 49)</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Aptos; padding-right: 5.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete Response </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Aptos; text-align: center; padding-right: 5.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9%</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Aptos; padding-right: 5.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Partial Response</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Aptos; text-align: center; padding-right: 5.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27%</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Aptos; padding-right: 5.75pt">Duration of Response<SUP>c</SUP></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Aptos; text-align: center; padding-right: 5.75pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Aptos; padding-left: 0.25in; padding-right: 5.75pt">Range, months</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Aptos; text-align: center; padding-right: 5.75pt">3.0+, 23.5+</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Aptos; padding-left: 0.25in; padding-right: 5.75pt">Duration &ge; 6 months, n (%)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Aptos; text-align: center; padding-right: 5.75pt">13 (52%)</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Aptos; padding-left: 0.25in; padding-right: 5.75pt">Duration &ge; 12 months, n (%)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Aptos; text-align: center; padding-right: 5.75pt">5 (20%)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><SUP>a</SUP></TD><TD STYLE="text-align: left">ORR, objective response rate per Olsen, et al (2011) Global
Response Score (GRS), by Independent Review Committee (IRC).</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><SUP>b</SUP></TD><TD STYLE="text-align: left">CI, confidence interval</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><SUP>c</SUP></TD><TD STYLE="text-align: left">The median (95% CI) DOR using Kaplan-Meier (KM) estimate
was not estimable (NE) among the 25 subjects due to censoring.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Median time to response was 1.4 months (range: 0.7 to 5.6 months).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Among responders, the median follow-up for duration of response was
6.5 months (range: 3.5+, 23.5+ months).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About LYMPHIR&trade; (denileukin diftitox-cxdl)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">LYMPHIR is a targeted immune therapy for r/r (R/R)
CTCL indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines
the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface,
causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the DT fragment is
cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death. Denileukin diftitox-cxdl demonstrated the ability
to deplete immunosuppressive regulatory T lymphocytes (Tregs) and antitumor activity through a direct cytocidal action on IL-2R-expressing
tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In 2021, denileukin diftitox received regulatory
approval in Japan for the treatment of CTCL and PTCL. Subsequently, in 2021, Citius acquired an exclusive license with rights to develop
and commercialize LYMPHIR in all markets except for Japan and certain parts of Asia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>About Cutaneous T-cell Lymphoma</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Cutaneous T-cell lymphoma is a type of cutaneous
non-Hodgkin lymphoma (NHL) that comes in a variety of forms and is the most common type of cutaneous lymphoma. In CTCL, T-cells, a type
of lymphocyte that plays a role in the immune system, become cancerous and develop into skin lesions, leading to a decrease in the quality
of life of patients with this disease due to severe pain and pruritus. Mycosis Fungoides (MF) and S&eacute;zary Syndrome (SS) comprise
the majority of CTCL cases. Depending on the type of CTCL, the disease may progress slowly and can take anywhere from several years to
upwards of ten to potentially reach tumor stage. However, once the disease reaches this stage, the cancer is highly malignant and can
spread to the lymph nodes and internal organs, resulting in a poor prognosis. Given the duration of the disease, patients typically cycle
through multiple agents to control disease progression. CTCL affects men twice as often as women and is typically first diagnosed in patients
between the ages of 50 and 60 years of age. Other than allogeneic stem cell transplantation, for which only a small fraction of patients
qualify, there is currently no curative therapy for advanced CTCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>INDICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">LYMPHIR is an IL2-receptor-directed cytotoxin
indicated for the treatment of adult patients with r/r Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic
therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>IMPORTANT SAFETY INFORMATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>BOXED WARNING: CAPILLARY LEAK SYNDROME</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Capillary leak syndrome (CLS), including life-threatening
or fatal reactions, can occur in patients receiving LYMPHIR. Monitor patients for signs and symptoms of CLS during treatment. Withhold
LYMPHIR until CLS resolves, or permanently discontinue based on severity.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>WARNINGS AND PRECAUTIONS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Capillary Leak Syndrome</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">LYMPHIR can cause capillary leak syndrome (CLS),
including life-threatening or fatal reactions. CLS was defined in the clinical trials as the occurrence of at least 2 of the following
symptoms at any time during LYMPHIR therapy: hypotension, edema, and serum albumin &lt;3 g/dL. These symptoms were not required to occur
simultaneously to be characterized as capillary leak syndrome.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As defined, CLS occurred in 27% of patients in
the pooled population across 3 clinical trials, including 8% with Grade 3. There was one (0.8%) fatal occurrence of CLS. Of the patients
with CLS, 22% had recurrence. The majority of CLS events (81%) occurred within the first 2 cycles of treatment. The median time to onset
from Cycle 1, Day 1 was 6.5 days (range: 1 to 77), the median duration of CLS was 14 days (range: 2 to 40), and 75% of patients had resolution.
The most common symptoms included edema, hypoalbuminemia, and hypotension. Pleural effusion, pericardial effusion, and dehydration also
occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Regularly assess patients for weight gain, new
onset or worsening of edema, dyspnea, and hypotension (including orthostatic changes). Monitor serum albumin levels prior to the initiation
of each cycle of therapy and more often as clinically indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Withhold, reduce dose, or permanently discontinue
based on severity. If LYMPHIR is withheld, resume LYMPHIR following resolution of CLS and when serum albumin is greater than or equal
to 3 g/dL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Visual Impairment </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">LYMPHIR can cause serious visual impairment, including
changes in visual acuity and color vision. In the pooled population across 3 clinical trials, visual impairment occurred in 9%, with Grade
1 in 8% and Grade 2 in 1%. The most commonly reported symptom was blurred vision. Of the patients with visual impairment, 67% had resolution
of their visual impairment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Perform baseline ophthalmic examination and monitor
as clinically indicated. If patients experience symptoms of visual impairment, such as changes in visual acuity, changes in color vision,
or blurred vision, refer for ophthalmologic evaluation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Withhold LYMPHIR until visual impairment resolves
or permanently discontinue based on severity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Infusion-Related Reactions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">LYMPHIR can cause serious infusion-related reactions.
Infusion-related reactions were reported in 69% of patients in the pooled population across 3 clinical trials of patients who received
LYMPHIR, with Grade 3 infusion-related reactions in 3.4% [see Adverse Reactions (6.1)]. Eighty-three percent of infusion-related reactions
occurred in Cycles 1 and 2. The most common symptoms included nausea, fatigue, chills, musculoskeletal pain, vomiting, fever, and arthralgia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Premedicate patients for the first three cycles
prior to starting a LYMPHIR infusion [see Dosage and Administration (2.3)]. Monitor patients frequently during infusion. For Grade 2 or
higher infusion reactions, premedicate at least 30 minutes prior to each subsequent infusion with a systemic steroid for at least 3 cycles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Interrupt or discontinue LYMPHIR based on severity
[see Dosage and Administration (2.4)]. Institute appropriate medical management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Hepatotoxicity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">LYMPHIR can cause hepatotoxicity. In the pooled
safety population, elevated ALT occurred in 70% of patients, with Grade 3 ALT occurring in 22%; elevated AST occurred in 64% of patients,
with Grade 3 AST elevation occurring in 9%. For Grade 3 events, median time to onset was 8 days (range: 1 to 15 days); median time to
resolution was 15 days (range: 7 to 50 days); all cases of Grade 3 ALT or AST elevations resolved [see Adverse Reactions (6.1)]. Elevated
total bilirubin occurred in 5% of patients, with Grade 3 occurring in 0.9%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Monitor liver enzymes and bilirubin at baseline
and during treatment as clinically indicated. Withhold, reduce dose, or permanently discontinue LYMPHIR based on severity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Embryo-Fetal Toxicity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Based on its mechanism of action, LYMPHIR can
cause fetal harm when administered to a pregnant woman. Verify the pregnancy status of females of reproductive potential prior to the
initiation of LYMPHIR. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective
contraception during treatment and for 7 days following the last dose of LYMPHIR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>ADVERSE REACTIONS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The most common adverse reactions (&ge;20%), including
laboratory abnormalities, are increased transaminases, albumin decreased, nausea, edema, hemoglobin decreased, fatigue, musculoskeletal
pain, rash, chills, constipation, pyrexia, and capillary leak syndrome</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>USE IN SPECIFIC POPULATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Pregnancy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Risk Summary</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Based on its mechanism of action, LYMPHIR can
cause fetal harm when administered to a pregnant woman. There are no available data on the use of LYMPHIR in pregnant women to evaluate
for a drug-associated risk. No animal reproductive and developmental toxicity studies have been conducted with denileukin diftitox.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Denileukin diftitox-cxdl causes depletion of regulatory
T lymphocytes (Treg), immune activation, and capillary leak syndrome, compromising pregnancy maintenance. Advise pregnant women of the
potential risk to a fetus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the U.S. general population, the estimated
background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2-4% and 15-20%, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Lactation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Risk Summary</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">No data are available regarding the presence of
denileukin diftitox-cxdl in human milk, the effects on the breastfed child, or on milk production. Because of the potential for serious
adverse reactions in breastfed children, advise women not to breastfeed during treatment with LYMPHIR and for 7 days after the last dose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Females and Males of Reproductive Potential
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Based on its mechanism of action, LYMPHIR can
cause fetal harm when administered to a pregnant woman.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Pregnancy Testing </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Verify the pregnancy status of females of reproductive
potential prior to initiating LYMPHIR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Contraception</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Females </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Advise females of reproductive potential to use
effective contraception during treatment with LYMPHIR and for 7 days after the last dose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Infertility</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Males</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Based on findings in rats, male fertility may
be compromised by treatment with. The reversibility of the effect on fertility is unknown.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Pediatric Use</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Safety and effectiveness of LYMPHIR in pediatric
patients have not been established.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Geriatric Use</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Of the 69 patients with Stage I-III r/r CTCL who
received LYMPHIR, 34 patients (49%) were 65 years of age and older and 10 patients (14%) were 75 years of age and older. Clinical studies
of LYMPHIR did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from
younger adult patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>You may report side effects to the FDA at 1-800-FDA-1088
or www.fda.gov/medwatch. You may also report side effects to Citius Pharmaceuticals at 1-844-459-6744.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Please read Important Safety Information and full
Prescribing Information, including Boxed WARNING, for LYMPHIR&trade; which will be available in the next few days</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>About Citius Pharmaceuticals, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Citius Pharmaceuticals, Inc. is a biopharmaceutical
company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved
LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma&#8217;s late-stage
pipeline also includes Mino-Lok&reg;, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections,
and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial
for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with
the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This press release may contain &#8220;forward-looking
statements&#8221; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements
by the fact that they use words such as &#8220;will,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221;
&#8220;should,&#8221; and &#8220;may&#8221; and other words and terms of similar meaning or use of future dates. Forward-looking statements
are based on management&#8217;s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating
results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated
are: our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets
for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life
of our target patient populations; the planned transaction between TenX Keane Acquisition and Citius Pharma to form Citius Oncology, Inc.
may not be completed for failure to meet closing conditions or other reasons; our need for substantial additional funds; risks relating
to the results of research and development activities, including those from our existing and any new pipeline assets; our dependence on
third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing
and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under
development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability
to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation;
competition; as well as other risks described in our SEC filings. These risks have been and may be further impacted by Covid-19 and could
be impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance,
and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail
in our Securities and Exchange Commission (&#8220;SEC&#8221;) filings which are available on the SEC&#8217;s website at www.sec.gov, including
in our Annual Report on Form 10-K for the year ended September 30, 2023, filed with the SEC on December 29, 2023, and updated by our subsequent
filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof, and we expressly
disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein
to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based,
except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investor Relations for Citius Pharmaceuticals:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investor Contact:</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ilanit Allen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ir@citiuspharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">908-967-6677 x113</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Media Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">STiR-communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Greg Salsburg</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Greg@STiR-communications.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex99-1_002.jpg" ALT=""></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ctxr-20240808.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 8qI5s7xRiXgen8uOYHxcWaiFucP9zp5yyZlBvGd/HckKTyYkjFhAhSroadNWYdoJ -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:CTXR="http://citiuspharma.com/20240808" elementFormDefault="qualified" targetNamespace="http://citiuspharma.com/20240808">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://citiuspharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="ctxr-20240808_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ctxr-20240808_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ctxr-20240808_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ctxr-20240808_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://citiuspharma.com/role/Cover" xlink:href="ctxr-20240808.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://citiuspharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  Q 2P# 2(  A$! Q$!_\0
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M_P!GCA\M_MRPJ,NM?ZE5?Y-W[<__ "L\^)O^TF_P&_\ 5G_""ORD_<#^M?\
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M@\0>#_%/A_X(:I>Z-XB\.ZYJ?A[6M%G&L:)']NTK4]$66YBO LCHGD@R;7=
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M$.B>)_$FDIX>\06/A[3?%^H3_#S3?#NG^*5\+WD=O=ZY?WGB61K0^&,?3O\
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M\!^'M1U&[O&;+_:KR5R9"_[PO(LF0& /\=?_  7E.?\ @H/XA([_  O^&O\
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M G67TOQ3K7V[SIX8VS9[HS*F\JI!K^ZK]J1PW[-/[1)5U^?X#_%QA&""V)?
MOB(1X ).)-DA3C#"-RN0K$?R4?\ !##Q!H/A7]L;Q?XE\3:WI'ASP[H7[/GQ
M$O=:\0:]J5EI&BZ/:6FM> 3=76J:KJ$UO8:?;VW_ "WGNYX8H?\ EHRUY/"J
MJX?)\_Q=&#G.E"#M&$Y6E.,G:?+&3LFDF]/6Z/I^/G'$<2\&915S6K1HYW*I
M&JW-0ARPV;E)PA&ZV4FOQ/++SXO_ /!0[_@F#\9[?P1XG\=^,-%U+3]*TW78
M_ OBOQ$_Q!^#_C7P5#<2V9U/2M/+SZ>-)BNH9K3[;I&H^%/&\=Q%+;V>G^#Y
M$=!_9-^S%\<-&_:/^ WPR^-OA^QFT^S\?^&8-7FTB64W+:)K$=R]EXBT(3KF
M*ZBT;Q!:WNEVMU&@C>WM-\8@5O*'\D'_  5Q_:S\!?MB?M!_#?PY\!X;SQGH
MOPOT5O!>B^)=)TZ8R^/O&/CC5[6[-AX6T\12:IJ6GW$T6A6?AIO+GCU2]NM1
MBTY9I"RG^HS_ ()Z?!;Q%^SO^QG\"?A'XTC2S\5^&?"]]J'B'3B9@-$UWQAX
MFUWQY=:*SSB*21M&?Q,NERH5/ERV#+SABE<90I3R7)<7CLIPF3Y[4NJGU=4U
M.4''[5%.517]U.,HW5W%W>B? E:=#B'/,KR[-\1G/#6312P]6NW4PSF[.U+%
M*^%J\KNKTJ\T[)^[=6_BHU3]J/XX>%_CKJ_Q#T+XH>.H+KPW\6]6\<V&C7OC
M+Q+>:)97]E\0&U33[2:Q<-%J&D7DH;0K72&1X[C30R11N@Q7][GP<^*/AOXU
M?"GX>?%OPE()-$^(WA+2/%NEJ9$E>V35M.2[GL;THQ$5YI5X9--U*!MDEGJ,
M$MI,D4Z-&O\  -\$_@SX@_:+G^/EYI$MW=^*OAS\%?''Q\-HK(4U:/P[XQ\,
MZ-XFTZW2-6:>5_#OC#Q#?:$B!C<:K9V"6V^5HQ7[2_\ !-C_ (*&6?P0_8)_
M:1\,^(]4M%\5? &&\\1?""TOG-PFJ0_$&YA\.Z9HUE;R'??6OAWXHW,U]JBV
M[2K8:/XKLY)XH[>WWCV.-\DPU:DHY=1G[:C)0K480FZL:=2-[3IQ@YQLU&:4
MH+3FV/F_#KB:IE>*S3#YUFM:I0J^_0JSNZ-1PNKTJLOW<WNOW=2>MD?-O_!6
M?]LKQG\1/VN/%7A#X=?$/Q1H'@;X,PQ_#*QA\*>*=8T2SU?Q/;7$FI?$:^O9
M+,B"2XT;Q)<6^C ^8WD0>#].C.Q=6@63^CS_ ()?>*-3\;_L'_L_ZYKFM7GB
M+5YM \0V=]JFH7IO[ZYFT'Q[XJ\/@7-RSNSRQ'2/LSJS%DDADA;#QE1_&3KO
MP3\9C]G"V_:J\47-_-!\1OC=/\-M#O+N4R3:U+#H>H:[XL\3-<RKY5[/J?B*
MXO\ 2I)H))3_ &GX=U.SD(N;&>./^N__ ((UW\=Y_P $\_@A!Y9B?2]0^*%E
M([ @3.?BYXUU9V#, "2VINF!_%'(#SNQR\88+ Y?PYDT<!9NE4=.HDX\\:T8
MM.$XK6%3F;<J;4)J_P #2/5\/LTS7,>+<YQ6/K1O.E[2G'GBKTKJU2"<DY4D
MK)5(J5/KSIFQ_P %5_CW>? W]BWXCZMH.I2:9XM^(#Z=\+O"]S;W"6EU9W'B
MYKJ'Q-=Z=<ADD.J:?X$T[Q?>:<("\Z:E9VJ(NY@1_*_^QQ^UK\3?A)^TY\%/
M'7BWXD^/=0\&P>+=,L_%-IXC\6Z]JVDW/A+Q1/\ \(UXNU">RN<P,^@Z9J^M
M7%F[%?)UNPLH?,CNE0#])/\ @OA\9QXD^*/P?_9]T2ZF>T\#:%=^,O$MM;N9
M89_$_CJ6"P\*6\\<195OM,TS0KZ^2)E2<:?XEN+@*8)1(WSU_P %1/V0H_V:
M_AY^Q5JEKIRQ7LGP;TWX=^/Y[2W:".;XC>#KIO'VI7EU,D48%[XFUWQ?KPM8
MIF^T7.E>'9!#YL&G2M%T\+T<GPV64,#F5-07$LJJ3G:G:$;N-I5'"[:VY>;W
MNZ1P\7YAGN,S_.LSR6I)Y9PW""=*DI5)2J67.U"FIOXO[OPKS/[,E?)'"\G:
M,>QP1WZ'J.QIS%<\@Y_G^HKXL_8!^-R?'O\ 9#^"'Q!N;]KK6/\ A#+'PGXN
MN;J4/>-XP\#;O"WB&YOPS;X9M5OM$EUJ,3[9)+/5+2Y4-%/&[_9PE4<-C(_O
M$ X]L]1Z&ORK$TG@L3/"SBE*FYQE&Z@[QDXWL[-*UGM]I'[E@\3#'X2EC*$D
MJ=9*4)NSC*-KWC)M1DO.,I+1V;+%%%%0=1_C)_'/PIJ?_!,?_@L%XUTSXC>"
MG\0Z9^S)^V!_PEU[X3U+3K.6+XF?!*R^(-GXLTC3#9ZR;>(:=\8?A?/;$N(F
MM8=%\:W=W%BUM/-'^E__ ,$H?V=?@WX)A^,/[2'[-OQ@\+?&+]FO]I/3_A_K
MWP4O_#^L76O:GH&@:9_;VMGPSXM^W833]?\ ##>)+31K72;T6^L>%WT^[L?$
MEC9ZC!);1>(_\%HO^"!GPD_X*LZ=I'Q*\+>)X?@5^U=X2TB/0=.^*<>FS:IX
M8^(GA>U%R]GX5^*N@VBQWNJ2Z5%<7>C>$_&]G,?$'AW3-9U6+5M/\8Z/%I_A
MN'^-J#_@W)_X.#_V8_$VH1_L[>&]5E>\N)_[2\<_LW?M;^!OA9:ZFB-Y<K2_
M\)E\2?@SXGU1+Y0H07N@6>5 8[4QCKH8[%T,+F>$A/W*BBTKWC/523CJKM-+
M6-WNFK/3S,1E&"Q>(RS-902JY&FJ2LE-W3B^6+2E)6[*6Z\S_4W%[9L[Q+=V
MS21K;-)&)XBZ+>.8[-G0/N5;IU9+8L )W!6(L017^3Q^W,"W_!SYXE0 ES_P
M4U^!$@0 EBB?$OX1S.X4<E$BBEE9L86..1R0J,1_3?\ \&\G_!(W_@J9^P=^
MU%\9_P!H+]M'6/!T?@?XJ?!N\^'^O>"[WXP3_%+XD^(_&*>.-!UOPIXEO'T:
MPUSPA-!H.DZ;XJMI+F[\96DT*>.6,44CW7B-=.\$_:/_ .#<7]OGXN?\%G;_
M /;P\.>+?V:X?@-J?[7?PK_:$2QUWQ[X^?Q9%X2\%>+_  7XFU31IO#"?"FX
MTU?%5U9^%[VS73I[V3PB_P!MCA.IB5LKR'99]G]S_P C^YRO\J;_ (.VR/\
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MN?\ D?MG_P &<.N_$'5?^"9GQ6TWQ4VHR^#M"_:[\=:?\.+_ %::[9)+*_\
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MIRFY4I.$4N:$)<UKW2YH[:Z/4^?X;R3%OBSBVOF^54ITJTH.A6G3O3JQ;O\
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E** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex99-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "( G # 2(  A$! Q$!_\0
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MTQ7BPZ5E05FT;XF7,HL[_P"%#-_;5\FX[3;@D>^X5ZQ7DWPI_P"0Y??]>_\
M[,*]9K"O\9T8;^&@HHHK$Z KA/BH[#P[;*&(5KD9'KP:[NN#^*O_ "+]I_U\
MC_T$UI2^-&5;^&SR2O;_ (>R/)X+LB[%B&D4$^@<X%>(5[;\.O\ D2K/_?D_
M]#-=6(^$XL+\9YS\069O&U\"Q(41@9/0;!63H#LGB/3&1BI^U1C(..K"M3X@
M?\COJ'_;/_T 5DZ%_P C#IG_ %]Q?^ABM(_P_D92_B/U/=_$$CP^'=2DC8HZ
M6LA5E."#M/(KYYR3R3DGO7T)XC_Y%G5?^O27_P!!-?/0Z"L<-LS?%[H6BNF\
M(>%%\4/=AKLVXMPG1-V[=G_"NI_X5-#_ -!:3_OT/\:UE5C%V9C&C.2ND>84
M5Z?_ ,*FA_Z"TG_?H?XT?\*FA_Z"TG_?H?XTO;P[C^KU.QYA4UO>75HVZVN9
MH6SG,;E?Y5Z2?A-%@XU:3/;,0_QKC?$OA:\\,W$:7#I-#+GRY4& <=01V-.-
M2$G84J4X*[1T7A7XB7<%W'::S)Y]O(=HG(^:,]L^HKTC5H-3NK:,:3?PVDN[
M+220>:&7'0#(]N:^>#R,&O>O!MZU_P"$M/F=MSB/RV/J5./Z5SUZ:7O(ZL-5
M<O=9R"^(?%L?@!O$'VZRN;JXV1VT M-H1S+LR3NYX_G6AXB\;W-OX<TB]TA8
MFN+S9-(LB[@D095DXSURP'UJW;>%]1@\(:-I/FP>?9WD<TQ#':R+(6('')P1
M5&?P'>&U\21Q3P$W8*Z8K$@6ZL_FL#QQ^\YX[ 5S'8=_16'J/BO3=)G\J]6Z
MB/9C VUOH>AJBWQ"T #B6X;Z0FLW4@M&S-U8)V;.JHKD3\1M%'1;D_\ ;.D_
MX6/HO_/.Z_[]_P#UZ7MJ?<GV]/\ F.OHKD/^%CZ+_P \[K_OW_\ 7H_X6/HO
M_/.Z_P"_?_UZ/;4^X>WI_P QU]%<A_PL?1?^>=U_W[_^O1_PL?1?^>=U_P!^
M_P#Z]'MJ?</;T_YCKZ*Y#_A8^C?\\[K_ +X'^-7]*\76FL7*0VMM<X8XWNH
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M#KJ5TH7CNS/GGEN9Y)YW,DLC%G9NI)KN/A[X3_M&Y75[Z/-I"W[E&'$CCO\
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M#AI&Z#_$^PK4ACBM4*VX()&&D;[S?X#VK.<XQ6I487W*\&FI#\]UAY/^>0/
M^I_H*]*\)Z4UM9_;9UQ-,/D7&-B=@!VS7+>'-(.JZDN]?]'B^:0^OH/QKTP
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M1P1,ML&_>W!'RJ.^/4^U>PV_@WP[;$&/2;?(.?G!?^9-;4<<<*!(D5$'15&
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MBSPW_P )-ID=H+G[.T<HD#[-PZ$8QD>M73:4DV9U8N4&D>#5[;\.O^1*L_\
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M*Y+Q;XMDT+4-!M[1[1Q?:@+:Y\PY,:;221@C!R.]=,E[:2.$2ZA=ST59 2:
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MS&LL;#NI&14Y02P;'&59<'W!%<?\+&8^!+>,G*PW-S$GLJS. /R% '9T444
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ME\<T 1>++5_%GQ#T+PW?7$T>DM8-?3V\+E/-<$@ D=N!^M;'_"I?!'_0%_\
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M#GQ#XKU>.XUFY;RVO;AMJ1DC/EQ+T48!]ZV(_'?A6:5(H]>L6D=@JJ).22<
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MZ=#XV^+E[HFKR3OI6DV,<J6B2%$D=\9+8()Z_I72#X8>#  /["AX_P"FC_\
MQ5<UJ>I0>"OBY>:WJT<R:3JUC'$EXB%TC=<9#8^GZUT'_"V/ _\ T'X_^_$O
M_P 30!G>*?AWX3L?".L7=MHT4<\-E-)&X=_E8(2#U]:YK6_^3?= _P!^U_\
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MX.0W;VJY?>)]%\,^&+&]F9X[22.-+2!$+2294;451R3C%>56A)_9FU4'H)6
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MBUN4V2Q'W%;[KO1E)(R",@X(^E>=>&_E^-WC!%X4VMLQ Z9VKS7HS,%4LQ
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MNE6AD-M;1^6AD;+8]S110!Y;XP@TK0O!UU\.= AU"\U*[*.D6PR%0\@;<S
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M/ZG=ZW=1/;V]O+%)BV+J5).XX3 )YHHH ]@\+Z5)HGA;3-,F</+;6Z1N1TW
J<X_&M:BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140716973238976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 08, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  08,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Citius Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001506251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3425913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11 Commerce Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">1st Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cranford<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">967-6677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CTXR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MY?.J>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^
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M$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ B$H(60=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" "(2@A9^N1:S>X    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " "(2@A9F5R<(Q &  "<)P  $P
M    @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( (A*"%GN
MBPS76 0  !H1   8              " @0T(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " "(2@A9GZ ;\+$"  #B#   #0
M    @ &;#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( (A*"%F7BKL<P
M !,"   +              "  7</  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M (A*"%FJQ"(6,P$  "("   /              "  6 0  !X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " "(2@A9)!Z;HJT   #X 0  &@
M@ ' $0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "(
M2@A999!YDAD!  #/ P  $P              @ &E$@  6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     "0 ) #X"  #O$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0210874-8k_citius.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://citiuspharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ctxr-20240808.xsd</File>
    <File>ctxr-20240808_lab.xml</File>
    <File>ctxr-20240808_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0210874-8k_citius.htm">ea0210874-8k_citius.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0210874-8k_citius.htm": {
   "nsprefix": "CTXR",
   "nsuri": "http://citiuspharma.com/20240808",
   "dts": {
    "schema": {
     "local": [
      "ctxr-20240808.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ctxr-20240808_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ctxr-20240808_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0210874-8k_citius.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://citiuspharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-08-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0210874-8k_citius.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-08-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0210874-8k_citius.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001213900-24-066357-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-066357-xbrl.zip
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MLMXE._"$20496L&[*B,L@ZM.O+D")1NAGV(H2:$N7L-)C IC/G7TAL:7/Z;
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M'FY:O\NELT+A"CXX82@<7G-PO/C ^7Q8Y._!XV]]4(G2=- 6HY/9!P+*!0S
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M!N):$6ND[S0)/2".L96.62S(;UCU61:D/FW7]6>T$QR1H2R;6:$NP06=*:3
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M^OG)AG*(0T@N<G>G2%+S)+Q'=)Y$B$E7#O/;4O+E79NO.%R^;(JS>S(.BPK
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MR]+*(K\^.#9?7QS_]@H?WEV?G;[Z/U!+ 0(4 Q0    ( (A*"%FN8,']+ ,
M .\+   1              "  0    !C='AR+3(P,C0P.# X+GAS9%!+ 0(4
M Q0    ( (A*"%E4*A_B_@H  ("&   5              "  5L#  !C='AR
M+3(P,C0P.# X7VQA8BYX;6Q02P$"% ,4    " "(2@A99PVL^5H'  #=5P
M%0              @ &,#@  8W1X<BTR,#(T,#@P.%]P<F4N>&UL4$L! A0#
M%     @ B$H(6=]"^*4K$@  R&\  !<              ( !&18  &5A,#(Q
M,#@W-"TX:U]C:71I=7,N:'1M4$L! A0#%     @ B$H(60V<O'+B*@  T=0
M !P              ( !>2@  &5A,#(Q,#@W-# Q97@Y.2TQ7V-I=&EU<RYH
8=&U02P4&      4 !0!4 0  E5,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>ea0210874-8k_citius_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ctxr-20240808.xsd" xlink:type="simple"/>
    <context id="AsOf2024-08-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506251</identifier>
        </entity>
        <period>
            <startDate>2024-08-08</startDate>
            <endDate>2024-08-08</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-08-08" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-08-08" id="Fact000004">0001506251</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-08-08" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-08-08" id="Fact000010">2024-08-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-08-08" id="Fact000011">Citius Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-08-08" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-08-08" id="Fact000013">001-38174</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-08-08" id="Fact000014">27-3425913</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-08-08" id="Fact000015">11 Commerce Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-08-08" id="Fact000016">1st Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-08-08" id="Fact000017">Cranford</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-08-08" id="Fact000018">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-08-08" id="Fact000019">07016</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-08-08" id="Fact000020">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-08-08" id="Fact000021">967-6677</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-08-08" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-08-08" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-08-08" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-08-08" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-08-08" id="Fact000026">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-08-08" id="Fact000027">CTXR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-08-08" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-08-08" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
